Clinical and Angiographic Outcomes of Wingspan Stent Placement for Treatment of Symptomatic Intracranial Stenosis: Single Center Experience with 19 Cases.
10.7461/jcen.2012.14.3.157
- Author:
Jun Hyoung LEE
1
;
Ji Kwang YUN
;
Dae Won KIM
;
Sung Don KANG
Author Information
1. Department of Neurosurgery, Institute of Wonkwang Medical Science, School of Medicine, Wonkwang University, Iksan, Korea. kimdw@wku.ac.kr
- Publication Type:Original Article
- Keywords:
Intracranial stenosis;
Angioplasty;
Stent implantation;
Wingspan stent
- MeSH:
Angioplasty;
Angioplasty, Balloon;
Arteries;
Caves;
Constriction, Pathologic;
Endovascular Procedures;
Fistula;
Follow-Up Studies;
Humans;
Male;
Retrospective Studies;
Stents;
Stroke;
Subarachnoid Hemorrhage
- From:Journal of Cerebrovascular and Endovascular Neurosurgery
2012;14(3):157-163
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The limitations of medical management of symptomatic intracranial arterial stenosis (ICS) have prompted development of new strategies, including endovascular treatment. However, stenting of symptomatic ICS remains investigational. Here, we have reported and analyzed a series of 19 endovascular procedures involving placement of a Wingspan stent. METHODS: We conducted a retrospective review of a series of ICS in which patients were treated with percutaneous transarterial balloon angioplasty and stent placement (PTAS). Patients included in the study were diagnosed as symptomatic ICS between May 2010 and September 2011. RESULTS: Nineteen patients (median age, 65 years; 12 males, seven women) were treated with the Wingspan stent system for symptomatic ICS ranging from 50% to 99%. The technical success rate was 100%. The location of ICS included the internal carotid (n = 5; 1 petrous, 3 cavernous, and 1 clinoid segments), vertebral (n = 1; V4 segment), basilar (n = 1), and middle cerebral (n = 12; 9 M1, 3 M2) arteries. There was no occurrence of procedure-related mortality. Periprocedural morbidity occurred in two cases (10.5%), including carotid-cavernous fistula (n = 1) and subarachnoid hemorrhage (n = 1). No ipsilateral stroke was recorded beyond 30 days during a mean follow-up period of 13.2 months (range 9-19 months). Restenosis (> 50%) was observed in one patient (6.3%), who was asymptomatic, on follow-up imaging. CONCLUSION: Wingspan stent for symptomatic ICS can be performed with a high rate of technical success and acceptable periprocedural morbidity rates. Our initial experience indicates that this procedure represents a viable treatment option for this patient population.
